<?xml version="1.0" encoding="UTF-8"?>
<p>Considering all these, the neuroinvasive propensity has been manifested as a common feature of CoVs. Based on more similarity between SARS‐CoV and SARS‐CoV‐2, COVID‐19 may also have a similar potential. Recently, a study carried out by Mao et al
 <xref rid="jmv25918-bib-0038" ref-type="ref">
  <sup>38</sup>
 </xref> on COVID‐19 infected 214 patients found that around 88% of severe patients showed neurological manifestations like acute cerebrovascular disease (impaired consciousness). It is very important to note the fact that, previous reports
 <xref rid="jmv25918-bib-0007" ref-type="ref">
  <sup>7</sup>
 </xref>, 
 <xref rid="jmv25918-bib-0010" ref-type="ref">
  <sup>10</sup>
 </xref>, 
 <xref rid="jmv25918-bib-0013" ref-type="ref">
  <sup>13</sup>
 </xref> discussed above has documented few SARS‐CoV‐2 infected patients showed neurologic symptoms like nausea, headache, and vomiting. However, more convincing evidence for brain illness caused by COVID‐19 would include type 2 respiratory failure or specific focal neurological defects.
 <xref rid="jmv25918-bib-0039" ref-type="ref">
  <sup>39</sup>
 </xref> This should be established by virus detection in cerebrospinal fluid by polymerase chain reaction (PCR) or viral culture.
</p>
